Nevertheless, CANTOS catalysed a paradigm shift, reinforcing inflammation as a modifiable driver of atherosclerosis and stimulating subsequent investigations of alternative agents with more favourable safety profiles, such as low-dose colchicine and IL-6 pathway inhibitors [77,78]. This evidence concerns the gene IL6 and atherosclerosis.